Mitral Valve Regurgitation Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Mitral Valve Regurgitation Treatment Market is Segmented By Disease Type (Degenerative Mitral Regurgitation, Functional Mitral Regurgitation), By Treatment Type (Surgery, Mitral Transcatheter Edge-to-Edge Repair (TEER), Transcatheter Mitral Valve Replacement (TMVR), Drugs, Others), By Sales Channel (End-User, Distribution Channel), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Mitral Valve Regurgitation Treatment Market Overview

Global Mitral Valve Regurgitation Treatment Market is expected to reach at a high CAGR during the forecast period 2023-2030.

The global mitral valve regurgitation treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics such as increasing prevalence, rising clinical trials, research activities, and others. Government investments in better treatment will continue to drive and boost the global market. Mitral valve regurgitation is also known as mitral regurgitation, mitral insufficiency, and mitral incompetence.

The mitral valve regurgitation is the most common type of heart valve disease (valvular heart disease). Basically, treatment of mitral valve regurgitation may include regular monitoring, medications, or surgery. Some people with mitral regurgitation don't need treatment, especially when the regurgitation is mild. The surgery segment holds the largest market share and it is considered a first-line treatment for mitral valve regurgitation. 

Similarly, North America dominates the mitral valve regurgitation treatment market, capturing the largest market share owing to the region’s advanced healthcare infrastructure, favorable reimbursement policies, and presence of major players. 

Owing to the increasing prevalence of mitral valve regurgitation, growing awareness, rising clinical trials, increasing demand for innovative products, rising FDA approvals, and advancements in treatment options are the major factors expected to drive the global mitral valve regurgitation treatment market over the forecast period.

Mitral Valve Regurgitation Treatment Market Scope

For more details on this report Request for Sample

Mitral Valve Regurgitation Treatment Market Dynamics

Increasing Demand for Innovative Products is Expected to Drive the Growth of the Market

The increasing demand for innovative products is expected to drive the growth of the market over the forecast period. The currently available treatments, procedures, and therapeutics may not be effective for all patients, and there is also a need for new therapies and therapeutics that can achieve better and enhanced treatment results. Novel therapeutics aim to address the unmet needs associated with mitral valve repair by providing alternative or complementary treatment options.

For instance, on January 27, 2021, Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announced that it has successfully completed its first-in-human transseptal delivery of the AMEND annuloplasty ring. Valcare's AMEND mitral valve repair device is an innovative, clinically proven, D-shaped, semi-rigid closed ring with unique anchoring capabilities. AMEND is designed to provide clinical standard-of-care surgical treatment via safer and easier catheter-based procedures.

Moreover, the ongoing research activities on mitral valve regurgitation enhance the treatment opportunities with better patient outcomes, and the development of innovative treatment approaches has led to the discovery of potential novel therapeutic options such as various procedures, devices, and drugs for enhanced treatment. These advancements increase the way for the introduction of novel drugs and devices with different mechanisms of action.

Rising Regulatory Approvals and Clinical Trials is Also Expected to Drive the Growth of the Market

The rising regulatory approvals and the increasing clinical trials are expected to drive the growth of the market over the forecast period. Clinical trials build trust in patients about the safety and efficacy of the therapeutics and medical devices. The positive results from clinical trials can boost investor confidence. This increased confidence can attract funding for further research and development and conduct more clinical trials, allowing companies to invest in more innovative therapeutics and medical devices driving the market.

For instance, on June 19, 2023, China-based medical equipment company Valgen Medtech presented the 12-month results of the DRAGONFLY-DMR trial during the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) 2023. DragonFly is a transcatheter-edge-to-edge repair (TEER) therapy that has been successfully implanted in more than 300 patients in China.

Additionally, the increasing regulatory approvals for new treatment options, such as drugs, medical devices, or procedures, improve the range of therapeutic options available to patients and healthcare providers. This treatment expansion choice can increase the market growth as it meets the needs of individuals who not have responded well to existing therapeutics. Increasing regulatory approvals helps to boost the unmet medical needs. The regulatory approvals such as FDA approvals also increase the patient's trust in the usage of the therapeutics. 

For instance, on September 15, 2022, Edwards Lifesciences Corporation announced the company's PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation. 

Complications Associated with the Surgery is Expected to Hamper the Market's Growth

There are mild to severe complications associated with mitral valve regurgitation surgery, which is expected to hamper the market growth over the forecast period. Open-heart surgery, which is often required for mitral valve repair or replacement, carries some complications. These complications and risks includes infection, bleeding, blood clots, and anesthesia-related complications. Patients and physicians may be hesitant to choose surgical options due to these risks, potentially leading to a slower adoption of surgical products.

Further, the recovery time from open-heart surgery can be lengthy, with patients requiring several weeks to months for full recuperation. This extended recovery period can be a deterrent for patients, and it may lead to a preference for less invasive options like transcatheter procedures, impacting the market for surgical mitral valve products.

Mitral Valve Regurgitation Treatment Market Segmentation Analysis

The global mitral valve regurgitation treatment market is segmented based on disease type, treatment type, sales channel and region.

The Surgery Segment Accounted for Approximately 38.1% of the Mitral Valve Regurgitation Treatment Market Share

The surgery segment is expected to hold the largest market share over the forecast period. The surgery for mitral valve regurgitation includes mitral valve repair, minimally invasive mitral valve repair, and mitral valve replacement by using various types of devices for mitral valve repair. The mitral valve repair devices used in the surgery helps to reduce the backflow of the blood and also helps to restore the ability of the heart to pump efficient blood. Some devices also offers minimally invasive options.

For instance, on February 16, 2021, Abbott launched a new device to treat mitral regurgitation in India. The “Clip Delivery System” is a minimally invasive heart valve repair device that can be used on patients suffering from mitral regurgitation due to a heart defect or as a result of heart failure. This clip device repairs leaky mitral valves without open-heart surgery and is delivered to the heart through a vein in the leg. The device clips portions of the leaflets, or flaps, of the mitral valve together to reduce the backflow of blood and restore the heart’s ability to pump oxygenated blood more efficiently.

Moreover, surgery can either repair the existing mitral valve or replace it with a prosthetic valve. Mitral valve repair is preferred when possible, as it preserves the patient's natural valve and may offer better long-term outcomes. However, in some cases, replacement is necessary. Surgical repair or replacement of the mitral valve is a durable solution. Prosthetic valves can last for many years, and repair techniques can provide long-term relief from regurgitation.

Global Mitral Valve Regurgitation Treatment Market Geographical Share

North America Accounted for Approximately 39.2% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Advanced Healthcare Infrastructure

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare infrastructure. North America is usually known for its advanced healthcare infrastructure including hospitals, cardiac clinics, specialty clinics, research and academic centers, and others. The presence of advanced healthcare infrastructure helps in better treatment by using advanced technologies and devices.

Furthermore, North America is also known for the strong presence of major players such as pharmaceutical and medical device companies. The presence of major players actively involved in performing clinical trials and research activities leading to regulatory approvals such as FDA approvals for innovative products are seen in the region, which leads to market dominance in the region.

For instance, on October 19, 2022, NeoChord, Inc., a privately-held medical technology company, is leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation with more than a decade of commercial experience in treating over 1,800 patients globally with the transapical technology. The company announced that based on this clinical expertise, the Transcatheter NeXuS system has been developed to broaden patient access with a catheter-based approach. The company is now positioned to provide multiple solutions for more than 1 million patients in the United States and Europe requiring mitral chordal repair that remain untreated.

Mitral Valve Regurgitation Treatment Market Companies

The major global players in the mitral valve regurgitation treatment market include Abbott Laboratories, Edwards Lifesciences Corporation, LivaNova PLC, Medtronic, Neovasc Inc., NeoChord, Inc., HVR Cardio, Cardiac Dimensions, Cardiovalve Ltd. and Peijia Medical Limited. among others. 

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global mitral valve regurgitation treatment market. During the pandemic, many clinical trials, research activities, and regulatory approvals have been temporarily postponed due to the redirected focus on the COVID-19 pandemic and its related restrictions.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular cardiac check-ups, appointments, and consultations worldwide. Many hospitals are focused on COVID-19 cases, this reduces the heart-related treatments including the mitral valve regurgitation treatment.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials and medical devices. Movement restrictions and border closures delayed shipments and caused drugs and devices transportation delays. Additionally, some countries faced shortages of drugs and valve devices for treatment due to disruptions in their supply chain networks.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global mitral valve regurgitation treatment market. The conflict has less impact mainly due to the low prevalence and absence of key market players in this region. 

Key Developments

• On February 21, 2023, Cardiovascular surgeons at Orlando Health Heart and Vascular Institute are scrubbing in for heart surgery with robotic-assisted technology. The robotic cardiac surgery program is currently the only program of its kind in Orlando, providing robotic-assisted surgery for structural and valve disease. The robotic cardiac surgery program is the latest offering in the Comprehensive Mitral Center offering patients an array of treatment options for mitral valve disease.
• On November 6, 2021, Medtronic plc, a global leader in healthcare technology presented early data for its self-expanding Intrepid transcatheter mitral valve replacement (TMVR) system in patients with severe, symptomatic mitral valve regurgitation (MR) utilizing the transfemoral access route. Presented as Late-Breaking Clinical Science at the 33rd Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation, data from the first 15 patients enrolled in an Early Feasibility Study of the Intrepid Transfemoral System showed 100% survival and no stroke, a median procedure time of 46 minutes, and none/trace MR in all implanted patients at 30 days.
• On December 7, 2021, Venus Medtech announced the acquisition of Cardiovalve Ltd. The Cardiovalve system independently developed by the company is a transcatheter interventional replacement product for patients suffering from mitral or tricuspid regurgitation. Compared with products of the same kind, its transfemoral approach improves the safety of treatment in significant ways.

DataM Intelligence Opinion:

According to the DataM Intelligence, the mitral valve regurgitation market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence and innovative products for better patient outcomes. However, there are many complications associated with the surgery for mitral valve regurgitation, which is expected to hamper the market growth.

Moreover, many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment. Further, many clinical trials and research activities are still going for the development of therapeutic innovations, which is expected to growth of the global market in the upcoming years.

Why Purchase the Report?

• To visualize the global mitral valve regurgitation treatment market segmentation based on disease type, diagnosis, treatment type, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of mitral valve regurgitation treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global mitral valve regurgitation treatment market report would provide approximately 69 tables, 69 figures, and 189 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies